Interview with Jiyoung Ahn, PhD, author of Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer. Hosted by Vivek Subbiah, MD. Related Content:

• Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer

Interview with David Hui, MD, and Eduardo Bruera, MD, authors of Proportional Sedation for Persistent Agitated Delirium in Palliative Care: A Randomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content:

• Proportional Sedation for Persistent Agitated Delirium in Palliative Care

Interview with Thorir Einarsson Long, MD, PhD, and Ola Landgren, MD, PhD, authors of New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance. Hosted by Vivek Subbiah, MD. Related Content:

• New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance

Interview with Shruti Gupta, MD, MPH, author of Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury. Hosted by Vivek Subbiah, MD. Related Content:

• Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury

Interview with Jennifer M. Yeh, PhD, and Lisa R. Diller, MD, authors of Accelerated Aging in Survivors of Childhood Cancer—Early Onset and Excess Risk of Chronic Conditions. Hosted by Vivek Subbiah, MD. Related Content:

• Accelerated Aging in Survivors of Childhood Cancer—Early Onset and Excess Risk of Chronic Conditions
• On Accelerated Aging—A Phenomenon in Survivors of Childhood Cancer

Interview with Anand P. Jillella, MD, author of Academic-Community Partnership and Deaths in Promyelocytic Leukemia: The Nonrandomized ECOG-ACRIN EA9131 Trial. Hosted by Vivek Subbiah, MD. Related Content:

• Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality

Interview with Michael A. Postow, MD, author of Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy. Hosted by Vivek Subbiah, MD. Related Content:

• Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy

Interview with Katrina A. B. Goddard, PhD, author of Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020. Hosted by Vivek Subbiah, MD. Related Content:

• Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020

Interview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content:

• Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib

Interview with Maria E. Cabanillas, MD, author of Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content:

• Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma